FDA Guidance Will Detail Medicare Rx Law’s Effect On ANDA Reviews
This article was originally published in The Pink Sheet Daily
Executive Summary
The pending reference listed drug guidance will include questions & answers about the Medicare law’s Waxman/Hatch reforms, FDA Director of Regulatory Policy Dupont says. The guidance is expected “very shortly.”